课题基金 / 基金详情

CONTRAST MEDIA REDUCE CSF PRODUCTION MECHANISM/TOXICITY

CONTRAST MEDIA REDUCE CSF PRODUCTION MECHANISM/TOXICITY
造影剂降低 CSF 产生机制/毒性
批准号:
3179661
负责人:
Phillip Harnish
金额:
$8.77万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1985
资助国家:
美国
项目状态:
已结题
起止时间:
1985-09-30 至 1988-07-31

项目摘要

项目成果

Phillip Harnish的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The causes of the adverse responses to contrast media (CM) are not well understood but may involve CM-induced alterations of the central nervous system (CNS). The blood brain barrier (BBB) strictly controls access of substance to the CNS. The rate of cerebrospinal fluid (CSF) production is a key factor in eliminating substances from the CNS. These two factors thus maintain and control the chemical environment of the CNS. If either factor is disrupted, toxic manifestations could occur. Both factors can be altered by CM. Contrast media are up to several hundred times more toxic in the CNS than systemically, and are able to disrupt the BBB. Experiments in dogs from this laboratory show that moderate doses of both ionic and non-ionic intravenous CM substantially decrease CSF production. Therefore, CM might be expected to alter the environment of the CNS and result in toxicity. The mechanisms of CM effects on the production of CSF will be studied in the proposed work. Conscious and anesthetized laboratory animal models and in vitro preparations will be employed to determine: the mechanisms of CM-induced ecreased CSF production; the extent of CNS toxicity resulting from this action of CM; changes in the concentration, retention and kinetics of substances in the CNS caused by CM; enhancement by certain risk factors of CM-induced toxicity by additionally decreasing CSF production or by predisposing the BBB to damaging effects of CM; and if it is possible to protect from these effects of CM pharmacologically.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EVP-ABD for MRI of Liver Disease
EVP-ABD: AN IMPROVED LIVER SPECIFIC AGENT FOR MRI
EVP-ABD for MRI of Liver Disease
'MAGNETIC THALLIUM' FOR MRI OF ISCHEMIC HEART DISEASE
海外基金